

VENUE OF THE CONGRESS
Hotel Royal Continental Napoli
Via Partenope, 38, Napoli, Italy



MAJOR MEETING SPONSOR



MEETING SPONSOR



Johnson & Johnson



Segreteria AIOM

Segreteria Organizzativa

Aiom
Via Enrico Nöe, 23
20133 Milano
02. 70 63 02 79
fax 02. 23 60 018
aiom.segretario@aiom.it
www.aiom.it


Aiom
SERVIZI
Uffici (Milano e Roma)
info@aiomservizi.it
Provider ECM n.1462
Via Enrico Nöe, 23
20133 Milano
02. 26 68 31 29
Via Rimini, 25
00182 Roma
06. 69 36 65 85

OFFICIAL ANNUAL MEETING OF IQN PATH



12TH MEETING ON
EXTERNAL
QUALITY
ASSESSMENT
IN MOLECULAR
PATHOLOGY

Hotel Royal Continental Napoli
May 17-18, 2024 • Naples



PROGRAM

FRIDAY, MAY 17, 2024

09:00	Welcome and opening <i>Nicola Normanno</i>
09:30 - 10:45	Implementation of precision oncology on a global scale <i>Chairs: Xavier Matias-Guiu, Francesco Perrone</i>
09:30	The perspective of the medical oncologist (<i>Dario Trapani</i>)
09:45	The perspective of pathologist: experience from a tertiary centre (<i>Xavier Matias-Guiu</i>)
10:00	Methodological challenges (<i>Francesco Perrone</i>)
10:15	The Lancet Oncology Commission Initiative (<i>Andrew Biankin</i>)
10:30	The IQN Path Initiative (<i>Nicola Normanno</i>)
10:45	Panel discussion
11:00 - 11:30	Coffee break
11:30 - 12:45	IQN Path ongoing projects: an update <i>Chairs: Emina Torlakovic, Etienne Rouleau</i>
11:30	Pilot EQA scheme for HRD testing (<i>Arfa Maqsood</i>)
11:45	Pilot EQA scheme for fusion gene testing (<i>Rachel Taylor</i>)
12:00	Pilot EQA for liquid biopsy testing for multiple markers (<i>Sandi Deans</i>)
12:15	Limitations and challenges of Biomarker Testing in Lung Cancer (<i>Ales Ryska</i>)
12:30	Panel discussion
13:00 - 14:30	Lunch
14.30 - 16:00	Navigating the regulatory landscape: the implications of the new IVDR <i>Chairs: Simon Patton, Nicola Normanno</i>
14.30	Overview on challenges for biomarkers in clinical trials (<i>Massimo Di Maio</i>)
14.45	The EU 'COMBINE' project on IVD and drug development (<i>Dario Trapani</i>)
15.00	EU authority perspective: The new EU In Vitro Diagnostics Regulation and its impact on clinical trials with medicinal products (<i>Ditte Zerlang Andersen, Ugur Erman</i>)



	15.15	Biomarkers in oncology drug development: U.S Regulatory Perspective (<i>Reena Philip</i>)
	15.30	Panel discussion
16:00 - 17:00	New technologies IQN Path corporate members are invited to present new technologies/assays. <i>Chairs: Sandi Deans, Francesca Fenizia</i>	
17:00 - 17:15	Tea break	
17:15 - 18:30	General Meeting of IQN Path <i>All IQN Path Academic and Corporate Members are invited to participate.</i>	

SATURDAY, MAY 18, 2024

09:00 - 10:30	New IHC biomarkers for precision oncology <i>Chairs: Zongming Eric Chen, Paul Hofman</i>	
	09:00	MET (<i>Paul Hofman</i>)
	09:15	Claudins (<i>Bharat Jasani</i>)
	09:30	HER2-low (<i>Emina Torlakovic</i>)
	09:45	Artificial Intelligence for IHC biomarker testing (<i>Catarina Eloy</i>)
	10:00	Proficiency Testing for Artificial Intelligence for IHC biomarker testing (<i>Zongming Eric Chen</i>)
	10:15	Panel discussion
10:30 - 10:45	Coffee break	
10:45 - 11:45	Empowering precision oncology: the role of Molecular Tumor Boards <i>Chairs: Gennaro Daniele, Raffaella Casolino</i>	
	10:45	The IQN Path MTB project (<i>Francesca Fenizia</i>)
	11:00	Challenges in MTB: standardization of the procedures (<i>Benedikt Westphalen</i>)
	11:15	How to handle incidental findings (<i>Maurizio Genuardi</i>)
	11:30	Panel discussion
11:45 - 12:45	IQN Path new projects proposal	
12:45 - 14:00	Lunch	
15:00 - 15:30	Meeting closure	